Hepatitis B

Positive 1-year data on telbivudine presented for the treatment of chronic HBV

Published in Blood Weekly, November 27th, 2003

Idenix Pharmaceuticals, Inc., presented final 52-week results from an international phase IIb clinical trial of its lead drug candidate, telbivudine, at the 54th annual meeting of the American Association for the Study of Liver Diseases in Boston, Massachusetts.

This trial compared treatment with telbivudine alone or telbivudine in combination with lamivudine, with lamivudine monotherapy in patients with chronic hepatitis B.

The study demonstrated significantly better suppression of hepatitis B virus (HBV) replication and normalization of ALT (a measure of liver disease) with telbivudine compared to lamivudine monotherapy. Additional analyses of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-11-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry